Lexicon Pharmaceuticals | LXRX - Current Assets


Lexicon Pharmaceuticals reported $101.9M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Abbott USD 26B 1.16B Dec/2025
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Akebia Therapeutics USD 252.96M 5.38M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Illumina USD 3.29B 493M Dec/2025
Insmed USD 1.79B 137.6M Dec/2025
Ironwood Pharmaceuticals USD 273.84M 82.09M Sep/2025
J&J USD 55.62B 1.01B Dec/2025
Lexicon Pharmaceuticals USD 101.9M 20.63M Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
MannKind USD 291.58M 67.26M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Moderna USD 6.54B 54M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Thermo Fisher Scientific USD 28.71B 6.41B Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
United Therapeutics USD 3.7B 208.5M Dec/2025
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025